In data from the TCGA breast cancer study, Multi-Dendrix identified significant exclusivity of mutations in pathways involved in p53 signaling, PI3K/AKT signaling, cell-cycle checkpoints, and p38-JNK1 signaling. Here, TP53 is linked to breast cancer.